GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Wiley  (7)
  • Kim, Beom Kyung  (7)
  • English  (7)
  • 2020-2024  (7)
Material
Publisher
  • Wiley  (7)
Person/Organisation
Language
  • English  (7)
Years
  • 2020-2024  (7)
Year
  • 1
    Online Resource
    Online Resource
    Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir
    Wiley ; 2021
    In:  Journal of Viral Hepatitis Vol. 28, No. 1 ( 2021-01), p. 95-104
    Details
    In: Journal of Viral Hepatitis, Wiley, Vol. 28, No. 1 ( 2021-01), p. 95-104
    Abstract: Several prediction scores for the early detection of hepatocellular carcinoma (HCC) are available. We validated the predictive accuracy of age, albumin, sex, liver cirrhosis (AASL), RESCUE‐B, PAGE‐B and modified PAGE‐B (mPAGE‐B) scores in chronic hepatitis B (CHB) patients treated with entecavir (ETV) or tenofovir disoproxil fumarate (TDF). Between 2007 and 2014, 3171 patients were recruited (1645, ETV; 1517, TDF). The predictive accuracy of each prediction score was assessed. The mean age of the study population (1977 men; 1194 women) was 48.8 years. Liver cirrhosis was present in 1040 (32.8%) patients. During follow‐up (median, 58.2 months), 280 (8.8%) patients developed HCC; these patients were significantly older; more likely to be male; had significantly higher proportions of liver cirrhosis, hypertension and diabetes; and had significantly higher values for the four risk scores than those who did not develop HCC (all P   〈  .05). Older age (hazard ratio [HR] = 1.048), male sex (HR = 2.142), liver cirrhosis (HR = 3.144) and prolonged prothrombin time (HR = 2.589) were independently associated with an increased risk of HCC (all P   〈  .05), whereas a higher platelet count (HR = 0.996) was independently associated with a decreased risk of HCC ( P   〈  .05). The predictive accuracy of AASL score was the highest for 3‐ and 5‐year HCC predictions (areas under the curve [AUCs] = 0.818 and 0.816, respectively), followed by RESCUE‐B, PAGE‐B and mPAGE‐B scores (AUC = 0.780‐0.815 and 0.769‐0.814, respectively). In conclusion, four HCC prediction scores were assessed in Korean CHB patients treated with ETV or TDF. The AASL score showed the highest predictive accuracy.
    Type of Medium: Online Resource
    ISSN: 1352-0504 , 1365-2893
    URL: Issue
    URL: Article
    DOI: 10.1111/jvh.v28.1
    DOI: 10.1111/jvh.13411
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2007924-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Long‐term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study
    Wiley ; 2022
    In:  Journal of Viral Hepatitis Vol. 29, No. 4 ( 2022-04), p. 289-296
    Details
    In: Journal of Viral Hepatitis, Wiley, Vol. 29, No. 4 ( 2022-04), p. 289-296
    Abstract: Renal safety is a critical issue in chronic hepatitis B (CHB) patients receiving long‐term entecavir (ETV) or tenofovir disofuroxil fumarate (TDF) therapy. We investigated their effects on estimated glomerular filtration rate (eGFR). Treatment‐naive CHB patients receiving ETV or TDF for ≥1 year were recruited. The eGFR was assessed using the Chronic Kidney Disease Epidemiology Collaboration equation. We calculated average annual percent change (AAPC) in eGFR using Joinpoint regression. At the beginning of the observation, the ETV group had more unfavorable conditions than the TDF group: lower eGFR and higher FIB‐4 and APRI than the TDF group (all p   〈  .001). After 6 years of antiviral therapy, the mean eGFR in the ETV group ( n  = 1793) was maintained (96.0 at first year to 95.6 ml/min/1.73 m 2 at sixth year; AAPC −0.09%; p  = .322), whereas that in the TDF group ( n  = 1240) significantly decreased annually (101.9 at first year to 96.9 ml/min/1.73 m 2 at sixth year; AAPC −0.88%; p   〈  .001). Notably, in the TDF group, even patients without diabetes (AAPC −0.80%; p  = 0.001) or hypertension (AAPC −0.87%; p  = .001) experienced significant decrease in eGFR. Expectably, accompanying diabetes (AAPC −1.59%; p  = .011) or hypertension (AAPC −1.00%; p  = .002) tended to accelerate eGFR decrease. TDF treatment (odds ratio 1.66, p   〈  .001), along with eGFR 〈 60 ml/min/1.73 m 2 , serum albumin 〈 3.5 mg/dl, and hypertension, were independently associated with ongoing renal dysfunction, defined as a negative slope of the mean eGFR change. In conclusion, compared with ETV, long‐term TDF treatment induced slow, but progressive renal dysfunction. Although the annual eGFR change by TDF was small, careful monitoring is necessary, especially in patients requiring life‐long therapy.
    Type of Medium: Online Resource
    ISSN: 1352-0504 , 1365-2893
    URL: Issue
    URL: Article
    DOI: 10.1111/jvh.v29.4
    DOI: 10.1111/jvh.13656
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2007924-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Entecavir and tenofovir on renal function in patients with hepatitis B virus‐related hepatocellular carcinoma
    Wiley ; 2020
    In:  Journal of Viral Hepatitis Vol. 27, No. 9 ( 2020-09), p. 932-940
    Details
    In: Journal of Viral Hepatitis, Wiley, Vol. 27, No. 9 ( 2020-09), p. 932-940
    Abstract: The use of tenofovir disoproxil fumarate (TDF) is associated with a risk of renal dysfunction. We investigated whether TDF is associated with the deterioration of renal function in patients with hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) requiring frequent computed tomography (CT) evaluations and transarterial chemoembolization (TACE) sessions, when compared to entecavir (ETV). Between 2007 and 2017, 493 patients with HBV‐related HCC were enrolled. The number of CT evaluations and TACE sessions were collected through 3 years of follow‐up. The median age of the study population (373 men and 120 women; 325 with ETV and 168 with TDF) was 56.5 years. TDF was significantly associated with a serum creatinine increase (≥25% from the baseline; unadjusted hazard ratio [uHR] = 1.620) and an estimated glomerular filtration rate (eGFR) reduction ( 〈 20% from the baseline) (uHR = 1.950) (all P   〈  .05), when compared to ETV. In addition, CT evaluations ≥4 times/year were significantly associated with a serum creatinine increase (uHR = 2.709), eGFR reduction (uHR = 3.274) and chronic kidney disease (CKD) progression (≥1 CKD stage from the baseline) (uHR = 1.980) (all P   〈  .05). In contrast, TACE was not associated with all renal dysfunction parameters (all P   〉  .05). After adjustment, TDF use was independently associated with the increased risk of eGFR reduction (adjusted HR [aHR] = 1.945; P  = .023), whereas CT evaluation ≥4 times/year was independently associated with the increased risk of serum creatinine increase (aHR = 2.898), eGFR reduction (aHR = 3.484) and CKD progression (aHR = 1.984) (all P   〈  .01). In conclusion, patients with HBV‐related HCC treated with TDF and frequent CT evaluations should be closely monitored for the detection of associated renal dysfunction.
    Type of Medium: Online Resource
    ISSN: 1352-0504 , 1365-2893
    URL: Issue
    URL: Article
    DOI: 10.1111/jvh.v27.9
    DOI: 10.1111/jvh.13313
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2007924-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Risk stratification using sarcopenia status among subjects with metabolic dysfunction‐associated fatty liver disease
    Wiley ; 2021
    In:  Journal of Cachexia, Sarcopenia and Muscle Vol. 12, No. 5 ( 2021-10), p. 1168-1178
    Details
    In: Journal of Cachexia, Sarcopenia and Muscle, Wiley, Vol. 12, No. 5 ( 2021-10), p. 1168-1178
    Abstract: Sarcopenia is a significant indicator of the severity of non‐alcoholic fatty liver disease. We investigated whether sarcopenia could identify subgroups with different risk of liver fibrosis and atherosclerotic cardiovascular disease (ASCVD) among subjects with metabolic dysfunction‐associated fatty liver disease (MAFLD). Methods Subjects from the Korea National Health and Nutrition Examination Survey 2008–2011 were selected ( n  = 8361). Sarcopenia was defined using the sarcopenia index. Hepatic steatosis was defined as a fatty liver index ≥30. Significant liver fibrosis was defined as a fibrosis‐4 index (FIB‐4) ≥2.67 or the highest quartile of non‐alcoholic fatty liver disease fibrosis score (NFS). High probability of ASCVD was defined as ASCVD risk score 〉 10%. Results The mean age was 48.5 ± 15.6 years, and 42.6% of subjects were male. The prevalence of MAFLD was 37.3% ( n  = 3116 of 8361), and the proportion of sarcopenic subjects was 9.9% among those with MAFLD. After adjusting for confounders, the risk of significant liver fibrosis significantly increased from non‐sarcopenic subjects with MAFLD [odds ratio (OR) = 1.57 by FIB‐4 and 2.13 by NFS] to sarcopenic subjects with MAFLD (OR = 4.51 by FIB‐4 and 5.72 by NFS), compared with subjects without MAFLD (all P   〈  0.001). The risk for high probability of ASCVD significantly increased from non‐sarcopenic subjects with MAFLD (OR = 1.47) to sarcopenic subjects with MAFLD (OR = 4.08), compared with subjects without MAFLD (all P   〈  0.001). Conclusions The risks of significant liver fibrosis and ASCVD differed significantly according to sarcopenic status among subjects with MAFLD. An assessment of sarcopenia might be helpful in risk stratification among subjects with MAFLD.
    Type of Medium: Online Resource
    ISSN: 2190-5991 , 2190-6009
    URL: Issue
    URL: Article
    DOI: 10.1002/jcsm.v12.5
    DOI: 10.1002/jcsm.12754
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2586864-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Long‐term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B
    Wiley ; 2022
    In:  Journal of Gastroenterology and Hepatology Vol. 37, No. 1 ( 2022-01), p. 200-207
    Details
    In: Journal of Gastroenterology and Hepatology, Wiley, Vol. 37, No. 1 ( 2022-01), p. 200-207
    Abstract: Antiviral therapy (AVT) induces fibrosis regression in patients with chronic hepatitis B. We investigated long‐term effects of entecavir (ETV) versus tenofovir (TDF) on fibrotic burden. Methods Treatment‐naïve chronic hepatitis B patients who had begun ETV or TDF were recruited from four tertiary hospitals. The aspartate aminotransferase‐to‐platelet ratio index (APRI) and fibrosis index based on four factors (FIB‐4) were used to determine fibrotic burden. Results In the entire population ( n  = 3277), although patients treated with ETV had higher baseline APRI (1.71 vs 1.07, P   〈  0.001) and FIB‐4 (3.60 vs 2.80, P   〈  0.001) than those treated with TDF, significant fibrosis regression was identified during 6 years of AVT in both ETV (APRI, mean 1.71 → 0.48, P   〈  0.001; FIB‐4, mean 3.60 → 2.21, P   〈  0.001) and TDF groups (APRI, mean 1.07 → 0.43, P   〈  0.001; FIB‐4, mean 2.80 → 2.19, P   〈  0.001). In patients without cirrhosis ( n  = 2366), baseline APRI was significantly higher in ETV group than in TDF group (1.72 vs 0.97, P   〈  0.001); however, they became similar after 6 months. Similarly, baseline FIB‐4 was significantly higher in ETV group than in TDF group (3.25 vs 2.35, P   〈  0.001), but became similar from 4 to 6 years. In patients with cirrhosis ( n  = 911), baseline APRI (1.70 vs 1.34, P   〈  0.001) and FIB‐4 (4.62 vs 3.91, P  = 0.005) were higher in ETV group than in TDF, however, both parameters became statistically similar from 6 months to 6 years. Conclusion Significant regression of APRI and FIB‐4 was observed during long‐term ETV and TDF treatment. Despite higher baseline fibrotic burden in ETV group, fibrotic burden between the groups eventually converged through significant fibrosis regression after 1 to 4 years of AVT.
    Type of Medium: Online Resource
    ISSN: 0815-9319 , 1440-1746
    URL: Issue
    URL: Article
    DOI: 10.1111/jgh.v37.1
    DOI: 10.1111/jgh.15678
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2006782-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    A multi‐centre study of trends in hepatitis B virus‐related hepatocellular carcinoma risk over time during long‐term entecavir therapy
    Wiley ; 2020
    In:  Journal of Viral Hepatitis Vol. 27, No. 12 ( 2020-12), p. 1352-1358
    Details
    In: Journal of Viral Hepatitis, Wiley, Vol. 27, No. 12 ( 2020-12), p. 1352-1358
    Abstract: The risk of developing hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) is reduced by antiviral therapy. Here, we evaluated the chronological trends in HCC development risk starting in 2007, when entecavir reimbursement was first initiated in South Korea. Treatment‐naïve patients with chronic hepatitis B (CHB) receiving entecavir 0.5 mg/d were stratified into three groups according to entecavir start time: early (2007‐2010), middle (2011‐2012) and late (2013‐2014) cohorts Among 2442 patients, cumulative probabilities of developing HCC after 1, 3 and 5 years were, respectively, 1.7%, 5.1%, and 8.2% (early cohort; n = 672); 1.5%, 5.1% and 8.9% (middle cohort; n = 757); and 1.2%, 5.3% and 10.6% (late cohort; n = 1013; P   〉  .05 between each pair). Older age, male, positive hepatitis B e antigen, liver cirrhosis, Child‐Pugh class B (vs A) and lower platelet count significantly predicted HCC development in univariate analysis ( P   〈  .001), whereas entecavir start time (early vs middle vs late cohorts) did not affect the risk of HCC development ( P  = .457). A multivariate analysis revealed that older age (adjusted hazard ratio [aHR]=1.041), male gender (aHR = 2.069), liver cirrhosis (aHR = 3.771) and Child‐Pugh class B (vs A, aHR = 1.548) were independently associated with an increased risk of HCC development, whereas higher platelet count was independently associated with a reduced risk of HCC development (aHR = 0.993; all P   〈  .05). In conclusion, the risk of developing HCC among patients receiving entecavir in South Korea has been stable since 2007. To establish more effective HCC surveillance programs, further studies regarding the carcinogenic roles of nonviral factors are required.
    Type of Medium: Online Resource
    ISSN: 1352-0504 , 1365-2893
    URL: Issue
    URL: Article
    DOI: 10.1111/jvh.v27.12
    DOI: 10.1111/jvh.13384
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2007924-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    An observational study on long‐term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate
    Wiley ; 2020
    In:  Journal of Viral Hepatitis Vol. 27, No. 3 ( 2020-03), p. 316-322
    Details
    In: Journal of Viral Hepatitis, Wiley, Vol. 27, No. 3 ( 2020-03), p. 316-322
    Abstract: In patients with chronic hepatitis B (CHB), long‐term effects of tenofovir disoproxil fumarate (TDF) on renal function have been controversial. This study aimed to analyse the real‐world long‐term effects of TDF on renal function in Korean patients with CHB. We analysed a cohort of 640 treatment‐naïve patients with CHB who were treated with TDF between May 2012 and December 2015 at Severance Hospital, Seoul, Republic of Korea. The mean age was 48.3 years old, and 59.5% were male. The proportions of hypertension and diabetes mellitus (DM) were 11.6% and 14.2%, respectively, and that of liver cirrhosis was 20.8%. During the 5‐year follow‐up, using a linear mixed model, serum creatinine increased from 0.77 ± 0.01 mg/dL to 0.85 ± 0.02 mg/dL ( P   〈  .001), and eGFR decreased from 102.6 ± 0.6 mL/min/1.73 m 2 to 93.4 ± 1.4 mL/min/1.73 m 2 ( P   〈  .001). In subgroup analysis, eGFR was statistically more decreased in patients with age  〉  60 than ≦60 years old ( P  = .027), and in patients with diuretic use than without diuretic use ( P  = .008). In multivariate analysis, the independent risk factors for eGFR decrease  〉  20% were baseline eGFR  〈  60mL/min/1.73 m 2 ( P  = .034) and the use of diuretics ( P   〈  .001). CHB patients on TDF experienced greater reduction in renal function with age  〉  60 and with diuretic use compared to those without these characteristics. Baseline eGFR  〈  60 mL/min/1.73 m 2 and use of diuretics were independent risk factors of eGFR decline of more than 20% on TDF therapy.
    Type of Medium: Online Resource
    ISSN: 1352-0504 , 1365-2893
    URL: Issue
    URL: Article
    DOI: 10.1111/jvh.v27.3
    DOI: 10.1111/jvh.13222
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2007924-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...